Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
| Status: | Available |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/12/2018 |
| Contact: | Kathy Ales |
| Phone: | 609-921-7447 |
Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with
Lambert-Eaton myasthenic syndrome (LEMS).
Lambert-Eaton myasthenic syndrome (LEMS).
Inclusion Criteria:
- Age 18 years or older,
- Diagnosed with LEMS,
- If female, have a negative pregnancy test, and
- If premenopausal, be willing to practice an effective form of birth control during the
study,
- Tested and found by ECG not to have a prolonged QT syndrome,
- Agree to have a second ECG at the time of peak drug effect,
- Has understood and signed the Informed Consent.
Exclusion Criteria:
- Is known to have a sensitivity to 3, 4-DAP,
- Has a history of:
1. past or current seizures,
2. cardiac arrhythmia,
3. hepatic, renal or hematologic disease, or
4. severe asthma,
- Is believed by the investigator to be unable to comply with the protocol.
We found this trial at
1
site
Click here to add this to my saved trials
